iTeos Therapeutics Strengthens Leadership Team
09 juin 2020 01h01 HE
|
iTeos Therapeutics SA
iTeos Therapeutics Strengthens Leadership Team Matthew Gall joins as Chief Financial OfficerDr. Yvonne McGrath joins as Vice President of R&DPhilippe Brantegem joins as Vice President of Human...
iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers
27 févr. 2020 01h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers – First patient enrolled in dose escalation portion of...
iTeos Therapeutics to Present at Cowen 40th Annual Health Care Conference
24 févr. 2020 08h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics to Present at Cowen 40th Annual Health Care Conference Cambridge, MA and Gosselies, Belgium – February 24, 2020 – iTeos Therapeutics SA, a privately-held biotechnology company...
iTeos Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference
26 nov. 2019 07h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference Cambridge, MA and Gosselies, Belgium – November 26, 2019 – iTeos Therapeutics SA, a privately-held biotechnology...
iTeos Therapeutics Announces Appointment of Matthew Call as Chief Operating Officer
13 août 2019 08h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics Announces Appointment of Matthew Call as Chief Operating Officer Gosselies, Belgium and Cambridge, MA – 13 August, 2019 – iTeos Therapeutics SA, a privately-held biotechnology...
iTeos Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference
07 août 2019 08h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference Gosselies, Belgium and Cambridge, MA – August 7, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company...
iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019
29 mars 2019 08h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019 Gosselies, Belgium and...
iTeos Therapeutics Appoints Joanne Jenkins Lager, M.D., as Chief Medical Officer
26 mars 2019 08h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics Appoints Joanne Jenkins Lager, M.D., as Chief Medical Officer Gosselies, Belgium and Cambridge, MA – March 26, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company...
iTeos Therapeutics to Participate in Upcoming Conferences in November
07 nov. 2018 08h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics to Participate in Upcoming Conferences in November Gosselies, Belgium – November 7, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies,...
iTeos Therapeutics to Participate in Upcoming U.S. Conferences in September
29 août 2018 07h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics to Participate in Upcoming U.S. Conferences in September Gosselies, Belgium – August 29, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer...